Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...
KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...
Keytruda Qlex must be administered by a health care provider. The Food and Drug Administration (FDA) has approved Keytruda Qlex ™ (pembrolizumab and berahyaluronidase alfa-pmph) for patients aged 12 ...
The FDA approved Merck's Keytruda Qlex, a new under-the-skin version of the cancer drug that can be injected in just 1-2 minutes, offering faster and more convenient treatment than traditional IV ...
The FDA approved Merck's proposed method of administering its Keytruda cancer drug by injection rather than intravenous. Merck said Friday the injection, called Keytruda Qlex, has shown comparable ...
The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co. Inc.’s (NYSE:MRK) Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in ...
12h
Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook
Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback